Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Gire

Indication
Renal Cell Carcinoma (RCC); ccRCC; Renal Cell Carcinoma (Kidney Cancer)

Other upcoming events for TLX

Phase 3 ReadoutPhase 3 Topline: A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific
Phase 3 ReadoutPhase 3 Topline: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solutio
Phase 3 ReadoutPhase 3 Topline: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lute

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Gire — TLX Phase 3 Readout | BioSniper